Twist Bioscience (NASDAQ:TWST) Stock: Insider Emily Leproust Sells 655 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 655 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $200.00, for a total value of $131,000.00. Following the completion of the sale, the chief executive officer directly owned 613,044 shares in the company, valued at approximately $122,608,800. The trade was a 0.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Stock Up 8.7%

Shares of NASDAQ TWST traded up $16.33 during midday trading on Monday, reaching $205.00. 3,204,075 shares of the company’s stock were exchanged, compared to its average volume of 1,622,926. The business’s fifty day moving average price is $136.40 and its two-hundred day moving average price is $92.42. The stock has a market capitalization of $12.86 billion, a PE ratio of -92.34 and a beta of 2.19. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $207.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. During the same quarter in the prior year, the business earned $0.33 earnings per share. The firm’s revenue was up 23.2% compared to the same quarter last year. Analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. E. Ohman J or Asset Management AB acquired a new position in Twist Bioscience in the 2nd quarter worth about $853,000. Allspring Global Investments Holdings LLC acquired a new stake in Twist Bioscience during the 1st quarter valued at approximately $22,563,000. Bank of America Corp DE increased its position in shares of Twist Bioscience by 46.3% during the first quarter. Bank of America Corp DE now owns 584,261 shares of the company’s stock worth $27,764,000 after buying an additional 184,907 shares during the period. William Blair Investment Management LLC bought a new stake in Twist Bioscience during the second quarter valued at $223,722,000. Finally, Corient Private Wealth LP bought a new stake in shares of Twist Bioscience during the 2nd quarter valued at about $2,226,000.

Trending Headlines about Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist Bioscience reported approximately 23% year-over-year revenue growth in its latest quarter, reinforcing the company’s expansion narrative and helping support bullish sentiment. Twist Bioscience stock reports 23 percent revenue growth
• Positive Sentiment: Leerink raised its price target for TWST from $120 to $160, signaling improved analyst expectations. Although the revised target remains below the recent share price, the increase may have added to buying momentum. Leerink raises target for Twist Bioscience stock
• Positive Sentiment: The stock reached a new 52-week high, reflecting strong momentum and investor demand. TWST has benefited from enthusiasm around biotechnology and synthetic-DNA markets, as well as attention from actively managed biotech funds. Twist Bioscience reaches new 52-week high
• Neutral Sentiment: CEO Emily Leproust, CFO Adam Laponis, CAO Robert Werner, SVP Paula Green and insider Dennis Cho sold shares primarily to cover tax withholding tied to vested equity awards. The transactions totaled roughly $14.3 million, but the CEO’s sales were conducted under a pre-arranged Rule 10b5-1 plan, reducing their usefulness as a signal of deteriorating business prospects. Twist Bioscience insider transaction filing
• Negative Sentiment: Valuation and profitability remain risks: the company continues to report net losses, and its latest quarterly earnings per share missed estimates despite beating revenue expectations. The sharp rally also leaves the stock well above Leerink’s revised target, increasing the potential for volatility or profit-taking.

Wall Street Analysts Forecast Growth

TWST has been the topic of several recent analyst reports. Guggenheim lifted their price target on Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday. Robert W. Baird lifted their price objective on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, September 21st. Leerink Partners increased their price target on shares of Twist Bioscience from $160.00 to $190.00 and gave the company an “outperform” rating in a research report on Tuesday, September 29th. Finally, Piper Sandler boosted their target price on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $115.27.

Twist Bioscience Company Profile

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.